|
Cancer researchers in Japan say they may have found a way to help predict which mesothelioma patients are most likely to respond well to treatment with Alimta.
Alimta (pemetrexed) was FDA approved in 2004 for the treatment of mesothelioma, a virulent form of lung cancer linked to asbestos exposure. Alimta is often administered along with the platinum-based drug cisplatin, although this first-line mesothelioma treatment combination has been shown to have only limited success.
Read more
| 
